Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine C Coombs

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
JAMA Oncology|June 7, 2018
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid TumorsRyan N Ptashkin, Diana L Mandelker, Catherine C Coombs, et al.
Blood Cancer Journal|May 7, 2026
Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigationsNatalia Timofeeva, Breana Herrera, Hitomi Fujiwara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2018
Managing Clonal Hematopoiesis in Patients With Solid TumorsKelly L Bolton, Nancy K Gillis, Catherine C Coombs, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2025
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient PerspectiveDeborah M Stephens, Chris Stewart, Liza Avruch, et al.
American Journal of Hematology|January 27, 2021
Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemiaDaniel R Richardson, David M Swoboda, Dominic T Moore, et al.
Cell Stem Cell|August 15, 2017
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C Coombs, Ahmet Zehir, Sean M Devlin, et al.
Cancer|April 9, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025Alexey V Danilov, Catherine C Coombs, Tycel Phillips, et al.
Ebiomedicine|May 6, 2018
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating AgentsMatthieu Duchmann, Fevzi F Yalniz, Alessandro Sanna, et al.
Blood|June 11, 2024
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trialLindsey E Roeker, Jennifer A Woyach, Chan Y Cheah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced MalignanciesGerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
JAMA Oncology|June 7, 2018
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid TumorsRyan N Ptashkin, Diana L Mandelker, Catherine C Coombs, et al.
Blood Cancer Journal|May 7, 2026
Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigationsNatalia Timofeeva, Breana Herrera, Hitomi Fujiwara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2018
Managing Clonal Hematopoiesis in Patients With Solid TumorsKelly L Bolton, Nancy K Gillis, Catherine C Coombs, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2025
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient PerspectiveDeborah M Stephens, Chris Stewart, Liza Avruch, et al.
American Journal of Hematology|January 27, 2021
Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemiaDaniel R Richardson, David M Swoboda, Dominic T Moore, et al.
Cell Stem Cell|August 15, 2017
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C Coombs, Ahmet Zehir, Sean M Devlin, et al.
Cancer|April 9, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025Alexey V Danilov, Catherine C Coombs, Tycel Phillips, et al.
Ebiomedicine|May 6, 2018
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating AgentsMatthieu Duchmann, Fevzi F Yalniz, Alessandro Sanna, et al.
Blood|June 11, 2024
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trialLindsey E Roeker, Jennifer A Woyach, Chan Y Cheah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced MalignanciesGerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Pageof 9